NPM1 and acute myeloid leukemia: To our knowledge, this study is the first to show that JQ1 is active against the Ontario Cancer Institute (OCI)-AML3 cell line which carries mutations of the nucleophosmin (NPM1) and DNA methyltransferase 3 (DNMT3A) genes that are highly recurrent in AML and commonly associated with poor risk disease.